CPhI South America, ever since its inception, has gained reputation as the gateway event to the South American pharmaceutical market providing an open platform where exhibitors and attendees can find business and educational resources in one location.
The CPhI South America 2011, dedicated to the pharmaceutical ingredients market, is expected to outdo the 17 per cent year-over-year increase that was experienced in 2010 with more than 200 exhibitors and 5000 attendees over two days. The event will be held from August 25 to 26 at the Transamerica Expo Centre in Sao Paulo, Brazil and has projections for a record year.
In 2010, the event experienced a 17 per cent year-over-year increase in onsite visitors and this year is projected to increase to be the largest edition of the event in its four year history.
CPhI South America 2011 will once again host the ICSE pavilion for outsourced and contract services and the BioPh Trail which highlights companies with expertise in the bio-pharmaceutical industry, and will feature the introduction of an educational NexGen Conference Series.
From a business perspective, the event facilitates an environment where attendees can personally meet with representatives of leading pharmaceutical companies to network and generate new business, locate new suppliers and get updated about current developments in the industry.
From an educational perspective, the event is featuring the introduction of the NexGen Conference Series which offers attendees the opportunity to learn about the growing market. Topics include trend discussions about legislation in South America, strategizing for success, working with the upcoming patent expirations and new generic patents, plus pharma sourcing. Speakers will include representatives from local agencies such as Anvisa (National Health Surveillance Agency) and companies such as ABRIFAR, Pró Genéricos and Cristália.
"CPhI South America offers visitors direct access to the burgeoning growth in the South American pharmaceutical market. The hosting country of Brazil is the largest pharmaceuticals market in South America," says Annemieke Timmers, CPhI Global Brand Director.
"This rapid growth has made the South American pharmaceuticals market all the more attractive to multinational companies, especially those in generics, bio-pharmaceuticals and developed clinical trials, all sectors which are expanding rapidly. The location allows CPhI South America to build on our attendee offerings year over year and enables them to leverage the double-digit growth that this market has seen in the last five years."
Also closely mirroring the rapid expansion of the South American pharmaceutical market, in 2010 CPhI South America experienced a 41 per cent increase in registrations from international visitors. This number is expected to increase in 2011 and will further serve to offer exhibitors and attendees with a multitude of opportunities to get introduced to companies in both the local South American and global pharmaceutical markets.
CPhi South America 2011, will bring a wealth of opportunities to the pharmaceutical industry. With a rapidly emerging market second only to China and a growth rate exceeding that of the global average, South America continues to promote an attractive business arena to many Western firms.
The visitor's profile include CEOs & top executives, purchase executive, manufacturing engineers of pharmaceutical companies, R&D professionals, pharma machinery suppliers & distributors, pharma consultants, scientists and government experts .
The exhibitor's profile include suppliers of turnkey pharma plants, machinery & equipment for treatment of pharma raw materials, analytical instruments & lab reagents, testing instruments, microscopes, weighing machines, active pharma ingredients, tableting & capsulation unit, packaging materials, glassware and pharma publications.
With new patent legislation recently adopted by most countries in the region and a growing appetite for investing in generic drugs, CPhI South America is the catalyst that is required to bring the entire industry together.
Plans to bring “CPhI” to South America were first considered back in 2005/06. It was then clear that the region, led by Brazil, was poised to see steep rises in pharma demand. Correspondingly, there was clear potential for a dedicated event to serve the industry sectors that would be expanding.
CPhI and P-MEC South America debuted in Rio de Janeiro in August 2008, receiving positive responses from the industry and resulting in a nomination for 'Best Trade Launch Show Award' by the Association of Event Organisers (AEO). In 2009 CPhI South America moved to Transamerica Expo Center, in São Paulo with 206 exhibitors participating from 18 different countries.
Opened up in August of 2001, Transamerica Expo Center is one of the integral part of the conglomerate Alfa and is operating varied events segments from more than 20 years through the chain of hotels Transamerica. The centre is highly technological driven and therefore considered one of the best in Latin America. The centre has successfully organized more than 300 events and has become venue for major B2B exhibitions, conferences, sales conventions, concerts, product launches etc.
The place is well connected with public transportation means. Connectivity through metro, bus make it easy for visitors to reach at centre. The centre is situated close to other business centres and is surrounded with luxurious hotels which are offering high class amenities for business class.
Brazil is already the world's seventh largest economy and the largest pharmaceutical market in South America. The Brazilian healthcare industry is one of the emerging sectors of the nation and is likely to witness stupendous growth in coming years owing to enhanced private investments in this sector.
The demand and supply of drugs is an important factor that has spurred the growth of the healthcare industry and has attracted many private players to bid for tenders for the supply of essential drugs to the public healthcare facilities. Owing to this private sector investment, Brazil’s healthcare industry is expected to grow at a CAGR of around 14.5 per cent during 2010-2013, according to a research report.
For the past few years, Brazil has been the focus of investment among the world’s major emerging countries. Moreover, Brazil has entered the investment route of major multinational pharmaceutical companies. Acquisitions, mainly in the generic drugs segment, are estimated to be the focus of those companies in 2010 in the country. Large national laboratories that were considered as purchase target for the foreigners have also joined the consolidation movement and are now focusing on foreign markets for expansion.
Pharmaceutical demand will continue, fuelled by increasing disposable income, therefore the market outlook is positive for the 2011-2016 period. Higher consumption of patented and bioequivalent medicines in Brazil will continue, replacing consumption of similar medicines.
The generics industry in Brazil has registered a significant growth rate during the last few years. Brazilian generics market will continue to witness the same uptrend in next few years. It is expected that the generics market will post a CAGR of nearly 19 per cent during 2010 - 2012.
The pharmaceutical industry in Brazil has been continuously growing for the last few years although the concerns of high taxes on medicines present negative conditions. This strong growth could be attributed to the fact that the private players are making huge investments in this sector as Brazil has been graded as one of the most promising pharmerging countries across the world.
The growing healthcare spending and the epidemiological transitions have been resulting into the strong demand for high-priced drugs and expensive therapies. Moreover, the soaring demand for primary health care level drugs such as generics, antibiotics and OTC drugs will drive the industry growth in coming years. Demand for generic and OTC drugs will inflate in Brazil, as a number of drugs will lose their patents.
The Brazilian healthcare industry shows immense growth potential and requires the attention of existing as well as new players. There is a high demand for hospitals services and experienced healthcare professionals. Since the country is highly dependent on imported drugs, it has given room to private players to set up their own manufacturing capacities in the country.